An observational study in Respiratory Syncytial Virus, sponsored by Quidel Corporation. Completed at 17 sites in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2013-02-07.
Sponsored by Quidel Corporation · Observational
The objective of this study is to demonstrate the clinical performance of the Sofia RSV FIA with specimens from symptomatic pediatric subjects who are less than nineteen (19) years of age.
Quidel Corporation is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Recruitment of RSV symptomatic pediatric subjects who are less than nineteen (19) years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must present with one or more of the following to be eligible for enrollment:
Exclusion Criteria:
High level of sensitivity and specificity for performance vs. culture
Clinical performance will be based on comparison of the Sofia RSV FIA results to cell culture.
Time frame: Culture results within 48 hours of plating
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Quidel Corporation